We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.75%
2 Industrials 0.18%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MPT
251
PUT
Medical Properties Trust
MPT
$2.75B
– –
-600,000
Closed -$10.6M
OVID icon
252
CALL
Ovid Therapeutics
OVID
$435M
– –
-16,000
Closed -$92K
RPTX
253
DELISTED
Repare Therapeutics
RPTX
– –
-190,410
Closed -$5.86M
TECX
254
Tectonic Therapeutic
TECX
$527M
– –
-10,417
Closed -$1.63M
DCPH
255
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-100,000
Closed -$5.13M
EIGR
256
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-11,344
Closed -$2.77M
MRTX
257
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-549,000
Closed -$91.2M
RETA
258
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-117,100
Closed -$11.4M
APTX
259
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-495,490
Closed -$1.68M
SIOX
260
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-177,684
Closed -$820K
MYOV
261
CALL
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-200,000
Closed -$2.81M
CCXI
262
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-100,000
Closed -$5.48M
EPZM
263
DELISTED
Epizyme, Inc
EPZM
– –
-29,080
Closed -$347K
ARNA
264
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-5,000
Closed -$375K
DRNA
265
CALL
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-10,000
Closed -$179K
DRNA
266
PUT
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-10,000
Closed -$179K
GWPH
267
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$0 ﹤0.01%
+8
New +$896
PAND
268
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-260,000
Closed -$2.98M
EIDX
269
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-63,011
Closed -$3.18M
ARYBU
270
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
– –
-318,206
Closed -$3.5M
IMMU
271
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-16,100
Closed -$1.37M
AIMT
272
PUT
DELISTED
Aimmune Therapeutics
AIMT
– –
-326,500
Closed -$11.2M
HZNP
273
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-2,641
Closed -$196K
7 8 9 10
11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.